Skip to main content
. 2020 Dec 10;11:6335. doi: 10.1038/s41467-020-20138-8

Table 1.

Clinicopathological features of the 24 evaluable patients.

N 24
Interval surgery-Denosumab Median days (range) 13 (9–21)
Age Median years (range) 44 (35–51)
Size >2 cm 11 (45.8%)
Nodal status Positive 4 (16.7%)
Histological grade High 8 (33.3%)
Molecular subtypes LumA 10 (41.7%)
LumB 9 (37.5%)
HER2 4 (16.7%)
TNBC 1 (4.2%)
Immune response Percentage of patients 11 (45.8%)